Why Investors Are Psyched About Psychedelic Stocks – Investment Watch
triple-digit returns in the last year Optimism is brewing as governments grant research approvals for the study of psychedelics on mental health By some estimates, the psychedelic drugs market is projected to see compound annual growth (CAGR) of 16.3% to reach Psyched About Psychedelics Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards. And like biotech companies, they often report no revenues and are a volatile bunch. Awareness around mental health disorders is increasing, as are the number of people...
Source: investmentwatchblog.com